TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 172 filers reported holding TRAVERE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.45 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $41,766,000 | -31.2% | 4,671,859 | +18.2% | 0.05% | -24.6% |
| Q2 2023 | $60,720,000 | -25.9% | 3,953,114 | +8.5% | 0.07% | -28.9% |
| Q1 2023 | $81,969,000 | +9.6% | 3,644,687 | +2.5% | 0.10% | +10.2% |
| Q4 2022 | $74,785,000 | -8.3% | 3,556,112 | +7.4% | 0.09% | -12.0% |
| Q3 2022 | $81,585,000 | -8.2% | 3,310,256 | -9.8% | 0.10% | 0.0% |
| Q2 2022 | $88,893,000 | -4.5% | 3,668,679 | +1.5% | 0.10% | +40.8% |
| Q1 2022 | $93,104,000 | -20.4% | 3,612,901 | -4.1% | 0.07% | -26.8% |
| Q4 2021 | $116,956,000 | +22.0% | 3,767,892 | -4.7% | 0.10% | +18.3% |
| Q3 2021 | $95,833,000 | +67.9% | 3,951,841 | +1.0% | 0.08% | +74.5% |
| Q2 2021 | $57,082,000 | -16.5% | 3,912,413 | +42.9% | 0.05% | -51.5% |
| Q1 2021 | $68,357,000 | -9.3% | 2,737,553 | -1.0% | 0.10% | -11.8% |
| Q4 2020 | $75,331,000 | – | 2,763,922 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 1,028,875 | $25,351,000 | 8.34% |
| GREAT POINT PARTNERS LLC | 966,108 | $23,805,000 | 5.73% |
| Deep Track Capital, LP | 4,000,000 | $98,560,000 | 4.51% |
| RA Capital Management | 4,922,941 | $121,301,000 | 2.59% |
| ARMISTICE CAPITAL, LLC | 5,836,000 | $143,799,000 | 2.49% |
| Kynam Capital Management, LP | 416,729 | $10,268,000 | 2.16% |
| MPM BioImpact LLC | 276,460 | $6,812,000 | 1.61% |
| HighVista Strategies LLC | 110,698 | $2,728,000 | 1.56% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 186,019 | $4,582,000 | 1.47% |
| SECTORAL ASSET MANAGEMENT INC | 249,700 | $6,153,000 | 1.21% |